Sulpiride versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2009, Pages

  Omori, Ichiro M ^a   Wang, Jijun ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SULPIRIDE;

CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; MENTAL HEALTH; META ANALYSIS; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE SYNDROME; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 70349156863     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007811     Document Type: Review

References (61)

1. Mezquita Blanco J, Cubillo Sanchez J, Aizpiri Diaz J, Zubia Zubia B. Clinical trial with sulpiride and placebo in chronic schizophrenics study of 89 patients using the Harris-Letemendia-Willems scale [Ensayo clinico con Sulpiride y placebo en esquizofrenicos cronicos. Estudio de 89 enfermos, con aplicacion de la escala de Harris, Letemendia y Willems]. Archivos de Neurobiologia - Madrid 1972;35:453-472
2. Soni SD, Mallik A, Schiff AA. Sulpiride in negative schizophrenia - a placebo-controlled double-blind assessment. Human Psychopharmacology Clinical and Experimental 1990;5:233-238 (Pubitemid 20317533)
3. Benoit JC, Delagrange G, Richou A, Souchon G, Sow I, Sivadon P. Contribution to the clinical study of a new neuroleptic: sulpiride [Contribution a l'etude clinique d'un nouveau neuroleptique: le sulpiride]. Semaine des Hopitaux 1969;45(15):958-963
4. Gong B-Q, Mu J-M, Song H-L, Song L-X, Li D-J. A comparison study of using clozapine in combination with sulpiride and simple using clozapine or sulpiride in treatment schizophrenia. Journal of Chinease Clinical Medicine 2001;2(6):20-23
5. Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. International Clinical Psychopharmacology 2004;19(1):23-26 [MEDLINE: 15101566; MEDLINE: 23273711] (Pubitemid 38114620)
6. Liu QH, Li XL, Zhang YQ, Jin SL, Li ZC, Wang NS, Chu JF, Ma SX. A control study of clozapine in combination with sulpiride in alleviating the negative symptoms of schizophrenia. Chinese Journal of Psychiatry 1996;29(2):87-90. [CHINESE: Academic Journals]
7. Shiloh R, Zemishlany Z, Aizemberg D, Radwan M, Schwartz B, Dorfman-Etrog P, Modai I, Khaikin M, Weizman A. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. British Journal of Psychiatry 1997;171:569-573 (Pubitemid 27527329)
8. Wang CH, Qin TF, Lin YL, Zhao XF. A clinical effect and following-up study about sulpiride and clozapine for 105 cases of the schizophrenia type ?. Journal of Xinxiang Medical College 1994;11(2):148-151
9. Wu DC, Liu YZ, Luo LX. Clinical controlled studies of olanzapine combined with sulpiride therapy in refractory schizophrenia. Chinese Journal of Behavioral Medical Science 2005;14(7):639-641 [: CAJ; : WANFANG]
10. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, Tang JS. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4):572-578 [EMBASE: 2006275796]
11. Yang S, Liu G. Observation on intractable auditory hallucination treated by injecting sulpiride into acupoints. Journal of Practical Traditional Chinese Medicine 2000;16(7):24-25
12. Yao H. A double blind randomized study comparing clozapine and clozapine combination with sulpiride in the treatment of schizophrenia. Sichuan Mental Health 1999;12(4):250-251
13. Zhao H, Zhao J, Wang Q. Comparison of sulpiride and chlorpromazine in treatment of negative psychotic symptoms with chronic schizophrenia. Health Psychology Journal 2003;11(3):224-225
14. Zhu Y, Zhang S, Zhang D. A controlled trial comparing clomipramine and sulpiride as adjunct to clozapine in the treatment of negative symptoms of schizophrenia. Journal of Clinical Psychological Medicine 1999;9(4):204-205
15. Hong CW. The clinical efficacy of sulpiride in the treatment of type II schizophrenia. Chinese Journal of Neurology and Psychiatry 1995;28(3):141.
16. Altman DG, Bland JM. Detecting skewness from summary information. British Medical Journal 1996;313:1200. [: SUL020600]
17. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa, USA: University of Iowa, 1984.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, D.C: American Psychiatric Association, 1994.
19. Azorin JM, Dassa D, Jalfre M. The atypical neuroleptic concept [Le concept de neuroleptique atypique]. Encephale 1992;18(3):453-457
20. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al.Improving the quality of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-639 (Pubitemid 26278070)
21. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ (Clinical research ed.) 1997;315(7108):600. [PUBMED: 9302962]
22. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite.]. Therapie 1999;54(4):405-411 [PUBMED: 10667106]
23. Bratfos O, Haug JO. Comparison of sulpiride and chlorpromazine in psychoses. A double-blind multicentre study. Acta Psychiatrica Scandinavica 1979;60:1-9. (Pubitemid 9209058)
24. Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Annals of Pharmacotherapy 1995;2:152-160
25. Carrere J. Study of the effects of sulpiride on the mental state of 40 mental patients [Etude des effets du Sulpiride sur l'etat psychique de quarante malades mentaux]. Annales Medico Psychologiques Paris 1968;2:560-574
26. Chisholm D, Gureje O, Saldivia S, Villalon Calderon M, Wickremasinghe R, Mendis N, et al.Schizophrenia treatment in the developing world: an interregional and multinational cost-effectiveness analysis. Bulletin of the World Health Organization 2008;86(7):542-551 [PUBMED: 18670667] (Pubitemid 351931214)
27. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25-28th. Cape Town, South Africa. 2000.
28. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of general internal medicine : official journal of the Society for Research and Education in Primary Care Internal Medicine 1992;7(6):623-629 [PUBMED: 1453246]
29. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in medicine 2002;21(19):2971-2980 [PUBMED: 12325113]
30. Edwards JG, Alexander JR, Alexander MS, Gordon A, Zutchi T. Controlled trial of sulpiride in chronic schizophrenic patients. British Journal of Psychiatry 1980;137:522-529 (Pubitemid 11251319)
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997;315(7109):629-634 [PUBMED: 9310563] (Pubitemid 27387172)
32. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International journal of epidemiology 2002;31(1):140-149 [PUBMED: 11914310] (Pubitemid 34284916)
33. Fleischhacker WW, Czobor P, Hummer M, Kemmler G, Kohnen R, Volavka J. Placebo or active control trials of antipsychotic drugs?. Archives of General Psychiatry 2003;60(5):458-464 (Pubitemid 36539054)
34. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bulletin 1991;17(2):289-309.
35. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American journal of epidemiology 1999;149(9):876-883 [PUBMED: 10221325] (Pubitemid 29196701)
36. Guy W. Clinincal Global Impression (CGI). In: Early clinical drug evaluation (ECDUE) assessment manual for psychopharmacology. Washington DC: National Institute of Mental Health, 1976.
37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine 2002;21(11):1539-1558 [PUBMED: 12111919]
38. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. [The Cochrane Collaboration, 2008.]. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
39. Hyman S, Chisholm D, Kessler R, Patel V, Whiteford H. Mental disorders. Disease Control Priorities in Developing Countries. 2nd Edition. New York: Oxford University Press, 2006.
40. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) manual. North Tonawanda (NY): Multi-Health Systems, 1986.
41. Kerwin RW. The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research. The British journal of psychiatry : the journal of mental science 1994; Vol.164, issue 2:141-148 [PUBMED: 7513599]
42. Krawiecka M, Goldberg D, Vaughan M. A standardized psychiatric assessment scale for rating chronic psychotic patients. Acta psychiatrica Scandinavica 1977;55(4):299-308. [PUBMED: 855676] (Pubitemid 8090438)
43. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. The British journal of psychiatry : the journal of mental science 2005;187:366-371 [PUBMED: 16199797] (Pubitemid 41442390)
44. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia research 2005;79(2-3):231-238 [PUBMED: 15982856]
45. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. The British journal of psychiatry : the journal of mental science 2000;176:249-252 [PUBMED: 10755072] (Pubitemid 30179844)
46. Mason P, Harrison G, Glazebrook C, Medley I, Croudace T. The course of schizophrenia over 13 years. A report fromthe International Study on Schizophrenia (ISoS) coordinated by the World Health Organization. The British journal of psychiatry : the journal of mental science 1996;169(5):580-586 [PUBMED: 8932886] (Pubitemid 26373159)
47. Mauri MC, Leva P, Coppola MT, Altamura CA. L-sulpiride in young and elderly negative schizophrenics: clinical and pharmacokinetic variables. Progress in Neuro Psychopharmacology and Biological Psychiatry 1994;8(2):355-356 (Pubitemid 24102917)
48. Mauri MC, Bravin S, Bitetto A, Rudelli R, Invernizzi, G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Safety 1996;14(5):288-298 (Pubitemid 26164409)
49. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b (i)ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ (Clinical research ed.) 2003;326(7400):1171-1173 [PUBMED: 12775615] (Pubitemid 36649049)
50. Myamoto S, Stroup TS, Duncan GE, Aoba A, Lieberman JA. Acute pharmacological treatment of schizophrenia. In: Hirsch SR, Weinberger D editor(s). Schizophrenia. Second Edition. Oxford, UK: Blackwell Publishing, 2003:442-473
51. Nishiura, M. Clinico-pharmacological studies of sulpiride. Current Therapeutic Research 1976;20:164-172
52. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
53. Owens DGC, Johnstone EC. The disabilities of chronic schizophrenia: their nature and the factors contributing to their development. British Journal of Psychiatry 1980;136:384-395
54. Patel V. Mental health in low- and middle-income countries. British medical bulletin 2007;81-82:81-96. [PUBMED: 17470476] (Pubitemid 351194482)
55. Petit M, Zann M, Lesieur P, Colonna L. The effect of sulpiride on negative symptoms of schizophrenia. British Journal of Psychiatry 1987;150:270-271
56. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(4):399-409. [PUBMED: 15925493] (Pubitemid 40943544)
57. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
58. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA : the journal of the American Medical Association 1995;273(5):408-412 [PUBMED: 7823387]
59. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75. (Pubitemid 29201269)
60. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, Pinfold V, Takriti Y. [P85] The Leeds Outcomes Stakeholders Survey (LOSS) Study. 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007. 2007.
61. Soares B, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database of Systematic Reviews 1999, Issue 1. [DOI: 10.1002/14651858.CD001162.; PUBMED: 10796605]